Celgene Corp. (CELG)

78.63
NASDAQ : Health Technology
Prev Close 79.54
Day Low/High 78.34 / 79.56
52 Wk Low/High 74.13 / 147.17
Avg Volume 7.28M
Exchange NASDAQ
Shares Outstanding 724.83M
Market Cap 57.65B
EPS 3.80
P/E Ratio 22.16
Div & Yield N.A. (N.A)

Latest News

Emboldened By Biotech Names

Emboldened By Biotech Names

For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Stocks fall Thursday after Donald Trump calls off a summit meeting planned for next month with North Korea leader Kim Jong Un.

Celgene Shares Rise on Plans to Increase Stock Buybacks

Celgene Shares Rise on Plans to Increase Stock Buybacks

The Summit, N.J.-based biotech firm also plans to enter into an accelerated share repurchase program to buy back $2 billion of stock.

Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization And Plans To Execute A $2 Billion Accelerated Share Repurchase Program

Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization And Plans To Execute A $2 Billion Accelerated Share Repurchase Program

Celgene Corporation (NASDAQ: CELG) today announced that the Company's Board of Directors authorized the repurchase of an additional $3 billion of the Company's common stock.

Celgene Corp Becomes Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Celgene To Present New Clinical Data In Blood Cancer And Solid Tumor Therapies At Upcoming American Society Of Clinical Oncology (ASCO) Scientific Sessions

Celgene To Present New Clinical Data In Blood Cancer And Solid Tumor Therapies At Upcoming American Society Of Clinical Oncology (ASCO) Scientific Sessions

Celgene Corporation (NASDAQ: CELG) today announced that data from more than 60 company-sponsored, cooperative group and investigator-initiated clinical studies evaluating Celgene agents will be presented at the American Society of Clinical Oncology Annual...

Celgene Corporation To Webcast At Upcoming Investor Conferences And Events

Celgene Corporation To Webcast At Upcoming Investor Conferences And Events

Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences and events where Celgene management will provide an overview of the Company.

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

Jim Cramer: I Don't Have a Catalyst for Celgene or Gilead

After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

Video: Jim Cramer on Tesla, Biogen, Celgene and Groupon

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

What to Expect From Trump's Speech on Drug Prices on Friday

What to Expect From Trump's Speech on Drug Prices on Friday

Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.

CLASS UPDATE: The Klein Law Firm Reminds Investors Of A Class Action Commenced On Behalf Of Celgene Corporation Shareholders And A Lead Plaintiff Deadline Of May 29, 2018 (CELG)

CLASS UPDATE: The Klein Law Firm Reminds Investors Of A Class Action Commenced On Behalf Of Celgene Corporation Shareholders And A Lead Plaintiff Deadline Of May 29, 2018 (CELG)

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Celgene Corporation (NASDAQ: CELG) who purchased shares between January 12, 2015 and February 27, 2018.

CELG EXPANDED CLASS: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Celgene Corporation And A Lead Plaintiff Deadline Of May 29, 2018

CELG EXPANDED CLASS: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Celgene Corporation And A Lead Plaintiff Deadline Of May 29, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Celgene Corporation ("Celgene") (NASDAQ:CELG) securities...

CELGENE SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Celgene Corporation - CELG

CELGENE SHAREHOLDER ALERT: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Celgene Corporation - CELG

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS: CELG), if they purchased the Company's...

Dow Jumps 332 Points, Stocks Rally as Apple Hits All-Time High

Dow Jumps 332 Points, Stocks Rally as Apple Hits All-Time High

Stocks finish higher on Friday. A strong performance from Apple lifts the Dow.

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Celgene Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of May 29, 2018

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Celgene Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of May 29, 2018

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Celgene Corporation ("Celgene") (NASDAQ: CELG) between September 12, 2016 and February 27, 2018 .

Who Will Win This Game of 'World of Trade Warcraft,' the U.S. or China?

Who Will Win This Game of 'World of Trade Warcraft,' the U.S. or China?

The Chinese have something to lose here, and will not willingly surrender their position of superiority in trade.

Celgene Reports First Quarter 2018 Operating And Financial Results

Celgene Reports First Quarter 2018 Operating And Financial Results

Celgene Corporation (NASDAQ:CELG) reported net product sales of $3,531 million for the first quarter of 2018, a 20 percent increase from the same period in 2017.

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Jim Cramer weighs in on Waste Management, Blackstone Group, Xilinx, Celgene, Nvidia, Exelixis, Moneygram and more.

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Jim Cramer thinks that, finally, bargain hunters are just saying, "Enough already! It can't be that bad."

Kessler Topaz Meltzer & Check, LLP Announces Expanded Class Period In Securities Class Action Filed Against Celgene Corporation

Kessler Topaz Meltzer & Check, LLP Announces Expanded Class Period In Securities Class Action Filed Against Celgene Corporation

The law firm of Kessler Topaz Meltzer & Check, LLP announces that it has filed an expanded securities fraud class action complaint against Celgene Corporation (Nasdaq: CELG) ("Celgene" or the "Company") on behalf of investors who purchased the Company's...

The Klein Law Firm Announces A Class Action Commenced On Behalf Of Celgene Corporation Shareholders And A Lead Plaintiff Deadline Of May 29, 2018 (CELG)

The Klein Law Firm Announces A Class Action Commenced On Behalf Of Celgene Corporation Shareholders And A Lead Plaintiff Deadline Of May 29, 2018 (CELG)

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Celgene Corporation (NASDAQ: CELG) who purchased shares between September 12, 2016 and February 27, 2018.

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact The Firm

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Celgene Corporation To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Celgene Corporation...

Celgene Corporation Announces Appointment Of Jennifer Dudinak To Senior Vice President Of Global Regulatory Affairs

Celgene Corporation Announces Appointment Of Jennifer Dudinak To Senior Vice President Of Global Regulatory Affairs

Celgene Corporation (NASDAQ:CELG) today announced the appointment of Jennifer Dudinak, Pharm.

CELG INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Celgene Corporation And A Lead Plaintiff Deadline Of May 29, 2018

CELG INVESTOR ALERT: The Law Offices Of Vincent Wong Notifies Investors Of A Class Action Involving Celgene Corporation And A Lead Plaintiff Deadline Of May 29, 2018

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Celgene Corporation ("Celgene") (NASDAQ: CELG) securities...

New Analyses From Pivotal Phase III Trials Of Oral Ozanimod In Relapsing Multiple Sclerosis To Be Presented At The 2018 American Academy Of Neurology Annual Meeting

New Analyses From Pivotal Phase III Trials Of Oral Ozanimod In Relapsing Multiple Sclerosis To Be Presented At The 2018 American Academy Of Neurology Annual Meeting

Celgene Corporation (NASDAQ:CELG) today announced additional phase III data analyses evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 (S1P 1) and 5 (S1P 5) receptor modulator, versus interferon...

TheStreet Quant Rating: C (Hold)